Table 1 Characteristics of patients and target lesions
Prostate cancer | |||
|---|---|---|---|
No (n = 159) | Yes (n = 261) | P value | |
Age (years) | 66.7 ± 8.5 | 70.4 ± 7.8 | < 0.001 |
PSA (ng/mL) | 5.83 (4.60–8.09) | 7.97 (5.37–14.22) | 0.001 |
Prostate volume (cm3) | 41.2 ± 15.2 | 34.0 ± 15.1 | < 0.001 |
PSAD (ng/mL/cm3) | 0.15 (0.11–0.23) | 0.27 (0.17–0.47) | 0.002 |
Previous prostate biopsy history | 43 (27.0) | 41 (15.7) | 0.007 |
Positive systematic biopsy | 35 (22.0) | 233 (89.3) | < 0.001 |
Gleason grade group | < 0.001 | ||
1 | 17 (48.6) | 59 (25.3) | |
≥ 2 | 18 (51.4) | 174 (74.7) | |
No. of positive systematic biopsy cores | 0.6 ± 1.4 | 4.6 ± 3.4 | < 0.001 |
Target-lesion location | 0.642 | ||
Peripheral zone | 37 (23.3) | 66 (25.3) | |
Transitional zone | 122 (76.7) | 195 (74.7) | |
Target-lesion size (cm) | 1.01 ± 0.80 | 1.59 ± 1.09 | < 0.001 |
PI-RADS score | < 0.001 | ||
3 | 76 (63.9) | 43 (36.1) | |
4 | 75 (37.3) | 126 (62.7) | |
5 | 8 (8.0) | 92 (92.0) | |
Grayscale value | 70.3 (45.3–98.4) | 65.9 (47.7–89.9) | 0.359 |